Pediatric Vouchers Could Limit Adult Rare Disease Development, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency expands its critique of voucher incentive that it feels is a strain on agency resources.
You may also be interested in...
Priority Review Vouchers: Does Novartis Have User's Regret?
Stakeholders are sympathetic to FDA's concerns that voucher program requires diversion of precious resources, but some believe it provides substantial drug development incentive, particularly for small companies.
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.